Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients

NCT05352347 is registered in ClinicalTrials.gov with Shaperon as lead sponsor.

NCT NCT05352347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05352347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients
Lead sponsor
Shaperon
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 12, 2022
Completion date
December 31, 2024
Enrollment
1,134 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia